This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This SLC22A2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 57-89 amino acids from the N-terminal region of human SLC22A2.
OCT2 antikoerper, Oct2 antikoerper, Orct2 antikoerper, OCT2r antikoerper, rOCT2 antikoerper, Pou2f2 antikoerper, OCT2P antikoerper, oct1 antikoerper, wu:fc01b11 antikoerper, zgc:64076 antikoerper, slc22a2 antikoerper, solute carrier family 22 member 2 antikoerper, solute carrier family 22 (organic cation transporter), member 2 antikoerper, POU class 2 homeobox 2 antikoerper, solute carrier family 22 (organic cation transporter), member 2 L homeolog antikoerper, SLC22A2 antikoerper, Slc22a2 antikoerper, POU2F2 antikoerper, LOC521027 antikoerper, slc22a2 antikoerper, slc22a2.L antikoerper
Hintergrund
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.